__________________________________________________________________________________________
Re: Local ID TH140703890 / TH201407010484 FU (1)
Thank you for reporting to us a serious adverse event related to Lilly product.
We would like to collect more information to better understanding the reported event.
Please respond to following questions regarding the adverse event – Gastrointestinal Infections, involving a female patient, 74 Yrs. who was subscribed Forteo, reported the event to Lilly on 25/JUL/2014.
Please ask the HCP the following questions:
1. Please provide start date for the event and hospitalization dates
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
2. Concomitant medications,
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
3. What risk factors for the infections did the patient have?
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
4. What tests were done to determine the type of infection including microbiology and imaging?
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
5. What was the etiological infectious agent?
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
6. Corrective treatment, (What antimicrobial treatments were given and for how long?)
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
7. Were any other modes of treatment administered (please provide details)?
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
8. Event outcome
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
9. Relatedness of event to Forteo (If No, please provide rationale.)
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
Thanks
Yours sincerely,
ELI LILLY AND COMPANY
Sasithorn Suntharo
Pharmacovigilance Associate
HCP’s signature:
Date:
__________________________________________________________________________________
For Eli Lilly internal use only
Date of Confirmation of FU request sent to HCP:
Name and Designation: